4-Bromo-2-fluoro-N-methylbenzamide

4-Bromo-2-fluoro-N-methylbenzamide is a key synthetic intermediate with versatile applications in pharmaceutical research and development. The bromine substituent of 4-Bromo-2-fluoro-N-methylbenzamide enables selective palladium-catalyzed cross-coupling reactions including Suzuki-Miyaura, Buchwald-Hartwig, and Sonogashira couplings, allowing for the introduction of diverse aryl, amino, and alkynyl groups at the 4-position. The fluorine atom of 4-Bromo-2-fluoro-N-methylbenzamide influences the electronic properties of the aromatic ring and can improve metabolic stability and bioavailability of the final compounds. The N-methylamide functionality of 4-Bromo-2-fluoro-N-methylbenzamide serves as a hydrogen bond donor and acceptor, a feature commonly exploited in drug design for target engagement. 4-Bromo-2-fluoro-N-methylbenzamide is employed as a building block in the synthesis of pharmaceutical compounds, including potential therapeutic agents requiring halogenated benzamide scaffolds.

Product Parameters

Application

N-methyl-4-bromo-2-fluoro-benzamide is an intermediate in the synthesis of MDV 3100 (M199800), and is an androgen receptor antagonist that can block the binding of androgens to androgen receptors, and prevent nuclear translocation and the recruitment of co-activators. Ligand-receptor complex.

Synthetic Route

Add 4-bromo-2-fluorobenzoic acid (3.0 g, 13.7 mmol), 2 M methylamine aqueous solution (34.3 mL, 68.5 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 6.6 g, 34.25 mmol), 1-hydroxybenzotriazole (HOBt, 2.8 g, 20.6 mmol), N,N-diisopropylethylamine (DIPEA, appropriate amount) and N,N-dimethylformamide (DMF, 50 mL) into a 100 mL round-bottom flask. Stir the reaction mixture at room temperature for 16 hours. After the reaction is completed, add water (50 mL) to quench the reaction. Separate the aqueous phase, and extract the organic phase with ethyl acetate (3 × 50 mL). Combine the organic phases, dry over anhydrous sodium sulfate, filter and concentrate under reduced pressure. The crude product is purified by silica gel column chromatography with ethyl acetate/petroleum ether (1:3, v/v) as the eluent to obtain the title compound 4-bromo-2-fluoro-N-methylbenzamide as a white solid (2.34 g, yield 74%). Mass spectrometry (MS): [M+H]+ 232.

Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for 4-Bromo-2-fluoro-N-methylbenzamide that meets the expectations of pharmaceutical intermediate manufacturing:

Analytical characterization. Each batch undergoes analytical release testing including HPLC purity verification (>98.0%), melting point confirmation (125.0–129.0°C), NMR identity confirmation, and appearance verification (white to almost white powder to crystal) .

Batch traceability. From raw material procurement through final packaging, every step is documented and traceable. Each batch receives a unique lot number with retention samples maintained in accordance with Cosperpharm quality procedures.

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity data, melting point confirmation, and identity confirmation. Custom quality agreements are available upon request.

Customer-initiated quality audits. Qualified customers are welcome to audit Cosperpharm's manufacturing and quality control facilities. Please contact our regulatory team to schedule an audit.

Contact Us

Ready to secure 4-Bromo-2-fluoro-N-methylbenzamide for your cross-coupling synthesis or pharmaceutical intermediate program? Cosperpharm delivers high-quality halogenated benzamide building blocks with the documentation and supply reliability you need. Contact our team today—we're here to help you succeed from R&D to commercial manufacturing.